Anaptys Announces $100 Million Stock Repurchase Plan
Anaptys (Nasdaq: ANAB) announced an amended $100.0 million stock repurchase plan, in addition to $6.4 million remaining under the prior $75.0 million plan.
The company previously repurchased 3,443,188 shares, equal to 11.2% of shares outstanding before that repurchase program. Purchases may occur in open market transactions or under Rule 10b5-1/10b-18 programs.
Anaptys expects to end 2025 with approximately $300 million in cash, cash equivalents and investments, which includes an anticipated one-time $75 million commercial sales milestone from GSK tied to Jemperli reaching $1 billion in worldwide net sales. The repurchase plan expires March 31, 2026 and may be suspended or discontinued at any time; it does not obligate any repurchases.
Anaptys (Nasdaq: ANAB) ha annunciato un piano di riacquisto azionario modificato per 100,0 milioni di dollari, in aggiunta ai 6,4 milioni di dollari rimanenti del precedente piano da 75,0 milioni.
L'azienda ha precedentemente riacquistato 3.443.188 azioni, pari all'11,2% delle azioni in circolazione prima di quel programma di riacquisto. Gli acquisti possono avvenire in operazioni sul mercato aperto o nell'ambito dei programmi Rule 10b5-1/10b-18.
Anaptys prevede di chiudere il 2025 con circa 300 milioni di dollari in contanti, equivalenti in contanti e investimenti, inclusa una milestone di vendita commerciale una tantum di 75 milioni di dollari da parte di GSK legata al raggiungimento da parte di Jemperli di 1 miliardo di dollari di vendite nette mondiali. Il piano di riacquisto scade il 31 marzo 2026 e può essere sospeso o interrotto in qualsiasi momento; non impone alcun riacquisto.
Anaptys (Nasdaq: ANAB) anunció un plan modificado de recompra de acciones por 100,0 millones de dólares, además de 6,4 millones de dólares restantes del plan previo de 75,0 millones.
La empresa ya recompró 3.443.188 acciones, equivalente al 11,2% de las acciones en circulación antes de ese programa de recompra. Las compras pueden realizarse en operaciones en el mercado abierto o bajo los programas Rule 10b5-1/10b-18.
Anaptys espera terminar 2025 con aproximadamente 300 millones de dólares en efectivo, equivalentes de efectivo e inversiones, lo que incluye un hito de ventas comerciales único de 75 millones de dólares de GSK vinculado a que Jemperli alcance 1.000 millones de dólares en ventas netas mundiales. El plan de recompra vence el 31 de marzo de 2026 y puede ser suspendido o discontinuado en cualquier momento; no impone ninguna recompra.
Anaptys (나스닥: ANAB)가 1억 달러 규모의 수정된 자사주 매입 계획을 발표했으며, 이전의 7,500만 달러 계획에서 남아 있던 640만 달러를 추가로 포함합니다.
회사는 이전에 3,443,188주를 매입했고 이는 해당 매입 프로그램 이전의 발행주식의 11.2%에 해당합니다. 매입은 공개시장 거래 또는 Rule 10b5-1/10b-18 프로그램에 따라 이루어질 수 있습니다.
Anaptys는 2025년을 현금, 현금성 자산 및 투자자산으로 약 3억 달러를 보유한 채로 마무리할 것으로 기대하며, Jemperli가 전세계 순매출 10억 달러에 도달하는 것과 연계된 글락스(GSK)로부터의 일회성 상업 매출 마일스톤 7,5천만 달러를 포함합니다. 매입 계획은 2026년 3월 31일에 만료되며 언제든 중단되거나 중지될 수 있습니다; 이는 매입을 의무화하지 않습니다.
Anaptys (Nasdaq: ANAB) a annoncé un plan de rachat d'actions modifié d'un montant de 100,0 millions de dollars, en plus des 6,4 millions de dollars restants du plan précédent de 75,0 millions.
L'entreprise avait précédemment racheté 3 443 188 actions, soit 11,2 % des actions en circulation avant ce programme de rachat. Les rachats peuvent avoir lieu sur le marché libre ou dans le cadre des programmes Rule 10b5-1/10b-18.
Anaptys prévoit terminer 2025 avec environ 300 millions de dollars en liquidités, équivalents de liquidités et investissements, ce qui inclut une étape de vente commerciale unique de 75 millions de dollars de GSK liée au fait que Jemperli atteigne 1 milliard de dollars de ventes nettes mondiales. Le plan de rachat expire le 31 mars 2026 et peut être suspendu ou interrompu à tout moment; il n'oblige à aucune opération de rachat.
Anaptys (Nasdaq: ANAB) gab einen geänderten Aktienrückkaufplan in Höhe von 100,0 Millionen USD bekannt, zusätzlich zu 6,4 Millionen USD Rest aus dem bisherigen Plan von 75,0 Millionen.
Das Unternehmen hat zuvor 3.443.188 Aktien zurückgekauft, was 11,2% der vor diesem Rückkaufprogramm umlaufenden Aktien entspricht. Käufe können in offenen Markttransaktionen oder im Rahmen der Programme Rule 10b5-1/10b-18 erfolgen.
Anaptys erwartet, das Jahr 2025 mit ca. 300 Millionen USD in Barmitteln, Barmitteläquivalenten und Investitionen abzuschließen, einschließlich einer einmaligen Meilensteinzahlung von 75 Millionen USD von GSK im Zusammenhang mit dem Erreichen von 1 Milliarde USD Nettoumsatz weltweit durch Jemperli. Der Rückkaufplan läuft am 31. März 2026 ab und kann jederzeit ausgesetzt oder eingestellt werden; er verpflichtet zu keinem Rückkauf.
Anaptys (ناسداك: ANAB) أعلنت عن خطة إعادة شراء أسهم معدلة بقيمة 100.0 مليون دولار، بالإضافة إلى 6.4 ملايين دولار المتبقية من الخطة السابقة التي تبلغ 75.0 مليون دولار.
سبق أن أعادت الشركة شراء 3,443,188 سهمًا، وهو ما يعادل 11.2% من الأسهم القابلة للتداول قبل ذلك البرنامج. قد تتم عمليات الشراء في صفقات السوق المفتوح أو ضمن برامج Rule 10b5-1/10b-18.
تتوقع Anaptys أن تنتهي عام 2025 بما يقرب من 300 مليون دولار من النقد وما يعادله من النقد والاستثمارات، وهو ما يشمل هدفًا أحاديًا لمبيعات تجارية بقيمة 75 مليون دولار من GSK مرتبطًا بوصول Jemperli إلى 1 مليار دولار من المبيعات الصافية على مستوى العالم. ينتهي صلاحية خطة إعادة شراء الأسهم في 31 مارس 2026 وقد يتم تعليقها أو سحبها في أي وقت؛ وهي لا تُلزِم بأي عمليات شراء.
- Board authorized up to $100.0 million in share repurchases
- Previously repurchased 3,443,188 shares (~11.2% of shares outstanding)
- Plan may be suspended or discontinued at any time, limiting guaranteed buybacks
- Authorizing up to $100.0 million could reduce available cash resources if fully executed
SAN DIEGO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that its Board of Directors has authorized an amended Stock Repurchase Plan under which the Company may repurchase up to
Excluding any additional potential purchases under this Stock Repurchase Plan, Anaptys anticipates ending 2025 with approximately
The shares may be repurchased from time to time in open market transactions, or other means in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and Rule 10b-18 of the Exchange Act. The timing, number of shares repurchased, and prices paid for the stock under this program will depend on general business and market conditions as well as corporate and regulatory limitations, prevailing stock prices, and other considerations. The Stock Repurchase Plan will expire on March 31, 2026, may be suspended or discontinued at any time, and does not obligate the company to acquire any amount of common stock.
About Anaptys
Anaptys is a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics for autoimmune and inflammatory diseases. The company’s pipeline includes rosnilimab, a pathogenic T cell depleter, which has completed a Phase 2b trial for rheumatoid arthritis; ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease with plans to expand development into an additional indication; and ANB101, a BDCA2 modulator, in a Phase 1a trial. Anaptys has also discovered and out-licensed in financial collaborations multiple therapeutic antibodies, including a PD-1 antagonist (Jemperli (dostarlimab-gxly)) to GSK and an IL-36R antagonist (imsidolimab) to Vanda Pharmaceuticals. To learn more, visit www.AnaptysBio.com or follow us on LinkedIn.
Anaptys recently announced the intent to separate its biopharma operations from its substantial royalty assets by year-end 2026, enabling investors to align their investment philosophies and portfolio allocation with the strategic opportunities and financial objectives of each company. Learn more here.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to: the company’s ability to execute the Stock Repurchase Plan, in whole or in part; year-end cash estimates; the potential to receive any additional milestones and royalties from the GSK collaboration, and the timing therefor; and expectations regarding the structure, infrastructure, timing and taxation of the proposed separation into two companies. Statements including words such as “plan,” “continue,” “expect,” or “ongoing” and statements in the future tense are forward-looking statements. These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they do not fully materialize or prove incorrect, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements are subject to risks and uncertainties that may cause the company’s actual activities or results to differ significantly from those expressed in any forward-looking statement, including risks and uncertainties related to the company’s ability to advance its product candidates, obtain regulatory approval of and ultimately commercialize its product candidates, the timing and results of preclinical and clinical trials, the company’s ability to fund development activities and achieve development goals, the company’s ability to protect intellectual property and other risks and uncertainties described under the heading “Risk Factors” in documents the company files from time to time with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release, and the company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof.
Contact:
Nick Montemarano
Executive Director, Investor Relations
858.732.0178
investors@anaptysbio.com
FAQ
What size stock repurchase did Anaptys announce on November 21, 2025 (ANAB)?
How much remained under Anaptys' prior $75.0 million repurchase plan before the amendment?
How many shares has Anaptys repurchased to date and what percent of shares did that represent?
When does the Anaptys stock repurchase plan expire and can it be changed?
How will Anaptys execute repurchases under the ANAB plan?
What is Anaptys' expected cash position at the end of 2025 and does it include any milestones?
